Evidence map›Paper›PMID 39202931›Full record

ReviewMolecules (Basel, Switzerland)2024

Progress on the Anti-Inflammatory Activity and Structure-Efficacy Relationship of Polysaccharides from Medical and Edible Homologous Traditional Chinese Medicines.

Yuanyuan Zhang, Xiulian Lin, Li Xia, Suhui Xiong, Bohou Xia, Jingchen Xie, Yan Lin, Limei Lin, Ping Wu

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Recent advances inFrontiers in pharmacology · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuanyuan ZhangSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Xiulian LinSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Li XiaSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Suhui XiongSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Bohou XiaSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0000-0003-0570-2995
Jingchen XieSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0009-0002-8538-8878
Yan LinSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Limei LinSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Ping WuSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.

Funding

Li-mei Lin Z2023JBGS05
6 · The paper itself

Abstract

Medicinal food varieties developed according to the theory of medical and edible homologues are effective at preventing and treating chronic diseases and in health care. As of 2022, 110 types of traditional Chinese medicines from the same source of medicine and food have been published by the National Health Commission. Inflammation is the immune system's first response to injury, infection, and stress. Chronic inflammation is closely related to many diseases such as atherosclerosis and cancer. Therefore, timely intervention for inflammation is the mainstay treatment for other complex diseases. However, some traditional anti-inflammatory drugs on the market are commonly associated with a number of adverse effects, which seriously affect the health and safety of patients. Therefore, the in-depth development of new safe, harmless, and effective anti-inflammatory drugs has become a hot topic of research and an urgent clinical need. Polysaccharides, one of the main active ingredients of medical and edible homologous traditional Chinese medicines (MEHTCMs), have been confirmed by a large number of studies to exert anti-inflammatory effects through multiple targets and are considered potential natural anti-inflammatory drugs. In addition, the structure of medical and edible homologous traditional Chinese medicines' polysaccharides (MEHTCMPs) may be the key factor determining their anti-inflammatory activity, which makes the underlying the anti-inflammatory effects of polysaccharides and their structure-efficacy relationship hot topics of domestic and international research. However, due to the limitations of the current analytical techniques and tools, the structures have not been fully elucidated and the structure-efficacy relationship is relatively ambiguous, which are some of the difficulties in the process of developing and utilizing MEHTCMPs as novel anti-inflammatory drugs in the future. For this reason, this paper summarizes the potential anti-inflammatory mechanisms of MEHTCMPs, such as the regulation of the Toll-like receptor-related signaling pathway, MAPK signaling pathway, JAK-STAT signaling pathway, NLRP3 signaling pathway, PI3K-AKT signaling pathway, PPAR-γ signaling pathway, Nrf2-HO-1 signaling pathway, and the regulation of intestinal flora, and it systematically analyzes and evaluates the relationships between the anti-inflammatory activity of MEHTCMPs and their structures.

Indexed as

Anti-Inflammatory AgentsDrugs, Chinese HerbalMedicine, Chinese TraditionalPolysaccharidesAnimalsHumansInflammationStructure-Activity RelationshipAnti-Inflammatory AgentsDrugs, Chinese HerbalPolysaccharidesanti-inflammatoryconformational relationshipMAPK signaling pathwaymedicinal foodpolysaccharideToll-like receptor-related signaling pathway

Identifiers

PMID39202931
PMCPMC11356930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.